First Mercantile Trust Co. Sells 2,287 Shares of DexCom, Inc. (DXCM)
First Mercantile Trust Co. cut its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 13.7% during the second quarter, Holdings Channel reports. The firm owned 14,447 shares of the medical device company’s stock after selling 2,287 shares during the period. First Mercantile Trust Co.’s holdings in DexCom were worth $1,057,000 as of its most recent SEC filing.
Several other hedge funds have also bought and sold shares of DXCM. Sit Investment Associates Inc. increased its stake in DexCom by 159.8% in the first quarter. Sit Investment Associates Inc. now owns 23,900 shares of the medical device company’s stock worth $2,025,000 after buying an additional 14,700 shares during the period. Morgan Stanley increased its stake in DexCom by 18.0% in the first quarter. Morgan Stanley now owns 2,092,962 shares of the medical device company’s stock worth $177,336,000 after buying an additional 319,631 shares during the period. DUPONT CAPITAL MANAGEMENT Corp acquired a new stake in DexCom during the first quarter worth about $270,000. Swiss National Bank increased its stake in DexCom by 28.4% in the first quarter. Swiss National Bank now owns 299,500 shares of the medical device company’s stock worth $25,377,000 after buying an additional 66,200 shares during the period. Finally, Teachers Advisors LLC increased its stake in DexCom by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 184,560 shares of the medical device company’s stock worth $11,018,000 after buying an additional 7,050 shares during the period.
DexCom, Inc. (NASDAQ DXCM) opened at 69.60 on Friday. The firm’s 50-day moving average price is $71.12 and its 200 day moving average price is $75.17. The firm’s market cap is $6.02 billion. DexCom, Inc. has a 52 week low of $57.68 and a 52 week high of $96.38.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.07. The firm had revenue of $170.60 million during the quarter, compared to the consensus estimate of $166.54 million. DexCom had a return on equity of 3.68% and a net margin of 1.70%. The company’s revenue for the quarter was up 24.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.24) EPS. Equities analysts forecast that DexCom, Inc. will post ($0.77) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “First Mercantile Trust Co. Sells 2,287 Shares of DexCom, Inc. (DXCM)” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/first-mercantile-trust-co-sells-2287-shares-of-dexcom-inc-dxcm/1478230.html.
A number of equities analysts recently weighed in on DXCM shares. Canaccord Genuity restated a “buy” rating and set a $90.00 target price on shares of DexCom in a report on Wednesday, June 7th. Oppenheimer Holdings, Inc. set a $98.00 target price on shares of DexCom and gave the stock a “buy” rating in a report on Wednesday, May 3rd. BidaskClub upgraded shares of DexCom from a “hold” rating to a “buy” rating in a report on Wednesday, June 21st. Piper Jaffray Companies restated an “overweight” rating and set a $78.00 target price on shares of DexCom in a report on Monday, May 22nd. Finally, TheStreet upgraded shares of DexCom from a “d” rating to a “c-” rating in a report on Wednesday, August 2nd. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and fifteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $87.00.
In other DexCom news, EVP Steven Robert Pacelli sold 1,450 shares of DexCom stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $78.19, for a total value of $113,375.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Andrew K. Balo sold 3,200 shares of DexCom stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $69.06, for a total value of $220,992.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 36,375 shares of company stock valued at $2,549,351. Corporate insiders own 1.70% of the company’s stock.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.